Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Shafali SPURLING JESTE |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
EEG data collection in children with ASD: The role of state in data quality and spectral power / Charlotte DISTEFANO in Research in Autism Spectrum Disorders, 57 (January 2019)
[article]
Titre : EEG data collection in children with ASD: The role of state in data quality and spectral power Type de document : Texte imprimé et/ou numérique Auteurs : Charlotte DISTEFANO, Auteur ; Abigail DICKINSON, Auteur ; Elizabeth BAKER, Auteur ; Shafali SPURLING JESTE, Auteur Article en page(s) : p.132-144 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Intellectual disability EEG Spectral power Index. décimale : PER Périodiques Résumé : Background Electroencephalography can elucidate neurobiological mechanisms underlying heterogeneity in ASD. Studying the full range of children with ASD introduces methodological challenges stemming from participants’ difficulties tolerating the data collection process, leading to diminished EEG data retention and increased variability in participant ‘state’ during the recording. Quantifying state will improve data collection methods and aide in interpreting results. Objectives Observationally quantify participant state during the EEG recording; examine its relationship to child characteristics, data retention and spectral power. Methods Participants included 5–11 year-old children with ASD (N?=?39) and age-matched TD children (N?=?16). Participants were acclimated to the EEG environment using behavioral strategies. EEG was recorded while participants watched a video of bubbles. Participant ‘state’ was rated using a Likert scale (Perceived State Rating: PSR). Results Participants with ASD had more elevated PSR than TD participants. Less EEG data were retained in participants with higher PSR scores, but this was not related to age or IQ. TD participants had higher alpha power compared with the ASD group. Within the ASD group, participants with high PSR had decreased frontal alpha power. Conclusions Given supportive strategies, EEG data was collected from children with ASD across cognitive levels. Participant state influenced both EEG data retention and alpha spectral power. Alpha suppression is linked to attention and vigilance, suggesting that these participants were less ‘at rest’. This highlights the importance of considering state when conducting EEG studies with challenging participants, both to increase data retention rates and to quantify the influence of state on EEG variables. En ligne : https://doi.org/10.1016/j.rasd.2018.10.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371
in Research in Autism Spectrum Disorders > 57 (January 2019) . - p.132-144[article] EEG data collection in children with ASD: The role of state in data quality and spectral power [Texte imprimé et/ou numérique] / Charlotte DISTEFANO, Auteur ; Abigail DICKINSON, Auteur ; Elizabeth BAKER, Auteur ; Shafali SPURLING JESTE, Auteur . - p.132-144.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 57 (January 2019) . - p.132-144
Mots-clés : Autism spectrum disorder Intellectual disability EEG Spectral power Index. décimale : PER Périodiques Résumé : Background Electroencephalography can elucidate neurobiological mechanisms underlying heterogeneity in ASD. Studying the full range of children with ASD introduces methodological challenges stemming from participants’ difficulties tolerating the data collection process, leading to diminished EEG data retention and increased variability in participant ‘state’ during the recording. Quantifying state will improve data collection methods and aide in interpreting results. Objectives Observationally quantify participant state during the EEG recording; examine its relationship to child characteristics, data retention and spectral power. Methods Participants included 5–11 year-old children with ASD (N?=?39) and age-matched TD children (N?=?16). Participants were acclimated to the EEG environment using behavioral strategies. EEG was recorded while participants watched a video of bubbles. Participant ‘state’ was rated using a Likert scale (Perceived State Rating: PSR). Results Participants with ASD had more elevated PSR than TD participants. Less EEG data were retained in participants with higher PSR scores, but this was not related to age or IQ. TD participants had higher alpha power compared with the ASD group. Within the ASD group, participants with high PSR had decreased frontal alpha power. Conclusions Given supportive strategies, EEG data was collected from children with ASD across cognitive levels. Participant state influenced both EEG data retention and alpha spectral power. Alpha suppression is linked to attention and vigilance, suggesting that these participants were less ‘at rest’. This highlights the importance of considering state when conducting EEG studies with challenging participants, both to increase data retention rates and to quantify the influence of state on EEG variables. En ligne : https://doi.org/10.1016/j.rasd.2018.10.001 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371 The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials / Frederick SHIC in Molecular Autism, 13 (2022)
[article]
Titre : The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials Type de document : Texte imprimé et/ou numérique Auteurs : Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Minah KIM, Auteur ; Kelsey J. DOMMER, Auteur ; Simone HASSELMO, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Gerhard HELLEMAN, Auteur ; April R. LEVIN, Auteur ; Helen SEOW, Auteur ; Raphael BERNIER, Auteur ; Katarzyna CHARWASKA, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali SPURLING JESTE, Auteur ; Scott P. JOHNSON, Auteur ; Michael MURIAS, Auteur ; Charles A. NELSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara J. WEBB, Auteur ; James C. MCPARTLAND, Auteur Article en page(s) : 15 p. Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis/psychology Autistic Disorder/diagnosis Biomarkers Child Eye Movements Eye-Tracking Technology Humans Autism spectrum disorder Biological motion Eye tracking Face processing Gaze pattern Visual attention Index. décimale : PER Périodiques Résumé : BACKGROUND: Eye tracking (ET) is a powerful methodology for studying attentional processes through quantification of eye movements. The precision, usability, and cost-effectiveness of ET render it a promising platform for developing biomarkers for use in clinical trials for autism spectrum disorder (ASD). METHODS: The autism biomarkers consortium for clinical trials conducted a multisite, observational study of 6-11-year-old children with ASD (n=280) and typical development (TD, n=119). The ET battery included: Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks. A priori, gaze to faces in Activity Monitoring, Social Interactive, and Static Social Scenes tasks were aggregated into an Oculomotor Index of Gaze to Human Faces (OMI) as the primary outcome measure. This work reports on fundamental biomarker properties (data acquisition rates, construct validity, six-week stability, group discrimination, and clinical relationships) derived from these assays that serve as a base for subsequent development of clinical trial biomarker applications. RESULTS: All tasks exhibited excellent acquisition rates, met expectations for construct validity, had moderate or high six-week stabilities, and highlighted subsets of the ASD group with distinct biomarker performance. Within ASD, higher OMI was associated with increased memory for faces, decreased autism symptom severity, and higher verbal IQ and pragmatic communication skills. LIMITATIONS: No specific interventions were administered in this study, limiting information about how ET biomarkers track or predict outcomes in response to treatment. This study did not consider co-occurrence of psychiatric conditions nor specificity in comparison with non-ASD special populations, therefore limiting our understanding of the applicability of outcomes to specific clinical contexts-of-use. Research-grade protocols and equipment were used; further studies are needed to explore deployment in less standardized contexts. CONCLUSIONS: All ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA's Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials. En ligne : http://dx.doi.org/10.1186/s13229-021-00482-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477
in Molecular Autism > 13 (2022) . - 15 p.[article] The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials [Texte imprimé et/ou numérique] / Frederick SHIC, Auteur ; Adam J. NAPLES, Auteur ; Erin C. BARNEY, Auteur ; Shou An CHANG, Auteur ; Beibin LI, Auteur ; Takumi MCALLISTER, Auteur ; Minah KIM, Auteur ; Kelsey J. DOMMER, Auteur ; Simone HASSELMO, Auteur ; Adham ATYABI, Auteur ; Quan WANG, Auteur ; Gerhard HELLEMAN, Auteur ; April R. LEVIN, Auteur ; Helen SEOW, Auteur ; Raphael BERNIER, Auteur ; Katarzyna CHARWASKA, Auteur ; Geraldine DAWSON, Auteur ; James DZIURA, Auteur ; Susan FAJA, Auteur ; Shafali SPURLING JESTE, Auteur ; Scott P. JOHNSON, Auteur ; Michael MURIAS, Auteur ; Charles A. NELSON, Auteur ; Maura SABATOS-DEVITO, Auteur ; Damla SENTURK, Auteur ; Catherine A. SUGAR, Auteur ; Sara J. WEBB, Auteur ; James C. MCPARTLAND, Auteur . - 15 p.
Langues : Anglais (eng)
in Molecular Autism > 13 (2022) . - 15 p.
Mots-clés : Autism Spectrum Disorder/diagnosis/psychology Autistic Disorder/diagnosis Biomarkers Child Eye Movements Eye-Tracking Technology Humans Autism spectrum disorder Biological motion Eye tracking Face processing Gaze pattern Visual attention Index. décimale : PER Périodiques Résumé : BACKGROUND: Eye tracking (ET) is a powerful methodology for studying attentional processes through quantification of eye movements. The precision, usability, and cost-effectiveness of ET render it a promising platform for developing biomarkers for use in clinical trials for autism spectrum disorder (ASD). METHODS: The autism biomarkers consortium for clinical trials conducted a multisite, observational study of 6-11-year-old children with ASD (n=280) and typical development (TD, n=119). The ET battery included: Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks. A priori, gaze to faces in Activity Monitoring, Social Interactive, and Static Social Scenes tasks were aggregated into an Oculomotor Index of Gaze to Human Faces (OMI) as the primary outcome measure. This work reports on fundamental biomarker properties (data acquisition rates, construct validity, six-week stability, group discrimination, and clinical relationships) derived from these assays that serve as a base for subsequent development of clinical trial biomarker applications. RESULTS: All tasks exhibited excellent acquisition rates, met expectations for construct validity, had moderate or high six-week stabilities, and highlighted subsets of the ASD group with distinct biomarker performance. Within ASD, higher OMI was associated with increased memory for faces, decreased autism symptom severity, and higher verbal IQ and pragmatic communication skills. LIMITATIONS: No specific interventions were administered in this study, limiting information about how ET biomarkers track or predict outcomes in response to treatment. This study did not consider co-occurrence of psychiatric conditions nor specificity in comparison with non-ASD special populations, therefore limiting our understanding of the applicability of outcomes to specific clinical contexts-of-use. Research-grade protocols and equipment were used; further studies are needed to explore deployment in less standardized contexts. CONCLUSIONS: All ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA's Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials. En ligne : http://dx.doi.org/10.1186/s13229-021-00482-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477